Gilead (GILD) announced that the European Commission has granted marketing authorization for Yeytuo-the company’s twice-yearly injectable HIV-1 capsid inhibitor-for use as pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk who weigh at least 35kg. Yeytuo is the first and only twice-yearly PrEP option to be approved for use in the European Union’s 27 member states, as well as Norway, Iceland and Liechtenstein.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences’ Promising Phase 3 Study in Lung Cancer Treatment
- Gilead Sciences Advances HIV-1 Treatment with New Clinical Study on GS-3242
- Gilead Sciences Advances Ulcerative Colitis Treatment with New Filgotinib Study
- Gilead Sciences Advances in NSCLC Treatment: Key Study Update
- Gilead Sciences Advances Lung Cancer Treatment with New Clinical Study